Search

Your search keyword '"Belsito Petrizzi, Valeria"' showing total 19 results
Start Over Author "Belsito Petrizzi, Valeria"
19 results on '"Belsito Petrizzi, Valeria"'

1. Supplementary Table 2 from c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer

Author

Nebbioso, Angela, primary, Carafa, Vincenzo, primary, Conte, Mariarosaria, primary, Tambaro, Francesco Paolo, primary, Abbondanza, Ciro, primary, Martens, Joost, primary, Nees, Matthias, primary, Benedetti, Rosaria, primary, Pallavicini, Isabella, primary, Minucci, Saverio, primary, Garcia-Manero, Guillermo, primary, Iovino, Francesco, primary, Lania, Gabriella, primary, Ingenito, Concetta, primary, Belsito Petrizzi, Valeria, primary, Stunnenberg, Hendrik G., primary, and Altucci, Lucia, primary

Published
2023
Full Text
View/download PDF

2. Supplementary Figure 3 from c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer

Author

Nebbioso, Angela, primary, Carafa, Vincenzo, primary, Conte, Mariarosaria, primary, Tambaro, Francesco Paolo, primary, Abbondanza, Ciro, primary, Martens, Joost, primary, Nees, Matthias, primary, Benedetti, Rosaria, primary, Pallavicini, Isabella, primary, Minucci, Saverio, primary, Garcia-Manero, Guillermo, primary, Iovino, Francesco, primary, Lania, Gabriella, primary, Ingenito, Concetta, primary, Belsito Petrizzi, Valeria, primary, Stunnenberg, Hendrik G., primary, and Altucci, Lucia, primary

Published
2023
Full Text
View/download PDF

3. Supplementary Figure 5 from c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer

Author

Nebbioso, Angela, primary, Carafa, Vincenzo, primary, Conte, Mariarosaria, primary, Tambaro, Francesco Paolo, primary, Abbondanza, Ciro, primary, Martens, Joost, primary, Nees, Matthias, primary, Benedetti, Rosaria, primary, Pallavicini, Isabella, primary, Minucci, Saverio, primary, Garcia-Manero, Guillermo, primary, Iovino, Francesco, primary, Lania, Gabriella, primary, Ingenito, Concetta, primary, Belsito Petrizzi, Valeria, primary, Stunnenberg, Hendrik G., primary, and Altucci, Lucia, primary

Published
2023
Full Text
View/download PDF

4. Suppl. Methods from c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer

Author

Nebbioso, Angela, primary, Carafa, Vincenzo, primary, Conte, Mariarosaria, primary, Tambaro, Francesco Paolo, primary, Abbondanza, Ciro, primary, Martens, Joost, primary, Nees, Matthias, primary, Benedetti, Rosaria, primary, Pallavicini, Isabella, primary, Minucci, Saverio, primary, Garcia-Manero, Guillermo, primary, Iovino, Francesco, primary, Lania, Gabriella, primary, Ingenito, Concetta, primary, Belsito Petrizzi, Valeria, primary, Stunnenberg, Hendrik G., primary, and Altucci, Lucia, primary

Published
2023
Full Text
View/download PDF

5. Supplementary Figure 1 from c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer

Author

Nebbioso, Angela, primary, Carafa, Vincenzo, primary, Conte, Mariarosaria, primary, Tambaro, Francesco Paolo, primary, Abbondanza, Ciro, primary, Martens, Joost, primary, Nees, Matthias, primary, Benedetti, Rosaria, primary, Pallavicini, Isabella, primary, Minucci, Saverio, primary, Garcia-Manero, Guillermo, primary, Iovino, Francesco, primary, Lania, Gabriella, primary, Ingenito, Concetta, primary, Belsito Petrizzi, Valeria, primary, Stunnenberg, Hendrik G., primary, and Altucci, Lucia, primary

Published
2023
Full Text
View/download PDF

6. Supplementary Figure 2 from c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer

Author

Nebbioso, Angela, primary, Carafa, Vincenzo, primary, Conte, Mariarosaria, primary, Tambaro, Francesco Paolo, primary, Abbondanza, Ciro, primary, Martens, Joost, primary, Nees, Matthias, primary, Benedetti, Rosaria, primary, Pallavicini, Isabella, primary, Minucci, Saverio, primary, Garcia-Manero, Guillermo, primary, Iovino, Francesco, primary, Lania, Gabriella, primary, Ingenito, Concetta, primary, Belsito Petrizzi, Valeria, primary, Stunnenberg, Hendrik G., primary, and Altucci, Lucia, primary

Published
2023
Full Text
View/download PDF

7. Supplementary Figure 8 from c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer

Author

Nebbioso, Angela, primary, Carafa, Vincenzo, primary, Conte, Mariarosaria, primary, Tambaro, Francesco Paolo, primary, Abbondanza, Ciro, primary, Martens, Joost, primary, Nees, Matthias, primary, Benedetti, Rosaria, primary, Pallavicini, Isabella, primary, Minucci, Saverio, primary, Garcia-Manero, Guillermo, primary, Iovino, Francesco, primary, Lania, Gabriella, primary, Ingenito, Concetta, primary, Belsito Petrizzi, Valeria, primary, Stunnenberg, Hendrik G., primary, and Altucci, Lucia, primary

Published
2023
Full Text
View/download PDF

8. Supplementary Figure 4 from c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer

Author

Nebbioso, Angela, primary, Carafa, Vincenzo, primary, Conte, Mariarosaria, primary, Tambaro, Francesco Paolo, primary, Abbondanza, Ciro, primary, Martens, Joost, primary, Nees, Matthias, primary, Benedetti, Rosaria, primary, Pallavicini, Isabella, primary, Minucci, Saverio, primary, Garcia-Manero, Guillermo, primary, Iovino, Francesco, primary, Lania, Gabriella, primary, Ingenito, Concetta, primary, Belsito Petrizzi, Valeria, primary, Stunnenberg, Hendrik G., primary, and Altucci, Lucia, primary

Published
2023
Full Text
View/download PDF

9. Supplementary Table 1 from c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer

Author

Nebbioso, Angela, primary, Carafa, Vincenzo, primary, Conte, Mariarosaria, primary, Tambaro, Francesco Paolo, primary, Abbondanza, Ciro, primary, Martens, Joost, primary, Nees, Matthias, primary, Benedetti, Rosaria, primary, Pallavicini, Isabella, primary, Minucci, Saverio, primary, Garcia-Manero, Guillermo, primary, Iovino, Francesco, primary, Lania, Gabriella, primary, Ingenito, Concetta, primary, Belsito Petrizzi, Valeria, primary, Stunnenberg, Hendrik G., primary, and Altucci, Lucia, primary

Published
2023
Full Text
View/download PDF

10. Supplementary Figure 6 from c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer

Author

Nebbioso, Angela, primary, Carafa, Vincenzo, primary, Conte, Mariarosaria, primary, Tambaro, Francesco Paolo, primary, Abbondanza, Ciro, primary, Martens, Joost, primary, Nees, Matthias, primary, Benedetti, Rosaria, primary, Pallavicini, Isabella, primary, Minucci, Saverio, primary, Garcia-Manero, Guillermo, primary, Iovino, Francesco, primary, Lania, Gabriella, primary, Ingenito, Concetta, primary, Belsito Petrizzi, Valeria, primary, Stunnenberg, Hendrik G., primary, and Altucci, Lucia, primary

Published
2023
Full Text
View/download PDF

11. Supplementary Figure 7 from c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer

Author

Nebbioso, Angela, primary, Carafa, Vincenzo, primary, Conte, Mariarosaria, primary, Tambaro, Francesco Paolo, primary, Abbondanza, Ciro, primary, Martens, Joost, primary, Nees, Matthias, primary, Benedetti, Rosaria, primary, Pallavicini, Isabella, primary, Minucci, Saverio, primary, Garcia-Manero, Guillermo, primary, Iovino, Francesco, primary, Lania, Gabriella, primary, Ingenito, Concetta, primary, Belsito Petrizzi, Valeria, primary, Stunnenberg, Hendrik G., primary, and Altucci, Lucia, primary

Published
2023
Full Text
View/download PDF

12. Hematological Toxicity During Concomitant Treatment With Ruxolitinib and Avelumab for Merkel Cell Carcinoma

Author

Buonerba, Luciana, primary, Di Trolio, Rossella, additional, Grimaldi, Antonio, additional, Tucci, Aniello, additional, Leo, Emilio, additional, Ingenito, Concetta, additional, Costabile, Ferdinando, additional, Ragone, Gianluca, additional, Savastano, Beatrice, additional, Uzzauto, Maria Teresa, additional, Belsito Petrizzi, Valeria, additional, and Di Lorenzo, Giuseppe, additional

Published
2020
Full Text
View/download PDF

14. c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer

Author

Nebbioso, Angela, primary, Carafa, Vincenzo, additional, Conte, Mariarosaria, additional, Tambaro, Francesco Paolo, additional, Abbondanza, Ciro, additional, Martens, Joost, additional, Nees, Matthias, additional, Benedetti, Rosaria, additional, Pallavicini, Isabella, additional, Minucci, Saverio, additional, Garcia-Manero, Guillermo, additional, Iovino, Francesco, additional, Lania, Gabriella, additional, Ingenito, Concetta, additional, Belsito Petrizzi, Valeria, additional, Stunnenberg, Hendrik G., additional, and Altucci, Lucia, additional

Published
2017
Full Text
View/download PDF

15. Long Term Toxicity and Follow-up of Waldenstrom´s Macroglobulinemia Patients after Salvage Treatment with Fludarabine Cyclophosphamide Rituximab or Bendamustine and Rituximab

Author

Tedeschi, Alessandra, primary, Picardi, Paola, additional, Goldaniga, Maria Cecilia, additional, Margiotta Casaluci, Gloria, additional, Benevolo, Giulia, additional, Ferrero, Simone, additional, Varettoni, Marzia, additional, Baratè, Claudia, additional, Gini, Guido, additional, Visco, Carlo, additional, Motta, Marina, additional, Belsito Petrizzi, Valeria, additional, Zaja, Francesco, additional, Ravelli, Erica, additional, Gentile, Massimo, additional, Frustaci, Anna Maria, additional, Orsucci, Lorella, additional, Morra, Enrica, additional, Gaidano, Gianluca, additional, and Cairoli, Roberto, additional

Published
2015
Full Text
View/download PDF

17. Bendamustine and Rituximab Combination Is Safe and Effective As Salvage Regimen in Waldenstrom's Macroglobulinemia

Author

Tedeschi, Alessandra, primary, Benevolo, Giulia, additional, Casaluci Margiotta, Gloria, additional, Ferrero, Simone, additional, Picardi, Paola, additional, Varettoni, Marzia, additional, Baratè, Claudia, additional, Motta, Marina, additional, Gini, Guido, additional, Goldaniga, Maria Cecilia, additional, Visco, Carlo, additional, Zaja, Francesco, additional, Belsito Petrizzi, Valeria, additional, Ravelli, Erika, additional, Gentile, Massimo, additional, Urbano, Marina, additional, Franceschetti, Silvia, additional, Orsucci, Lorella, additional, Frustaci, Annamaria, additional, Riccomagno, Paola, additional, Ghione, Paola, additional, Gaidano, Gianluca, additional, Vitolo, Umberto, additional, and Morra, Enrica, additional

Published
2014
Full Text
View/download PDF

18. An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia.

Author

Montillo, Marco, Tedeschi, Alessandra, Belsito Petrizzi, Valeria, Ricci, Francesca, Crugnola, Monica, Spriano, Mauro, Spedini, Pierangelo, Ilariucci, Fiorella, Uziel, Lilj, Attolico, Immacolata, Vismara, Eleonora, De Blasio, Angelo, Zaccaria, Alfonso, and Morra, Enrica

Subjects
*FLUDARABINE, *CYCLOPHOSPHAMIDE, *ALEMTUZUMAB, *CHRONIC lymphocytic leukemia, *DRUG efficacy, *MONOCLONAL antibodies, *DISEASE progression, *PATIENTS
Abstract

Although combination regimens have improved outcomes over monotherapy in chronic lymphocytic leukemia (CLL), patients eventually relapse. Combined fludarabine, cyclophosphamide, and monoclonal anti-CD52 antibody alemtuzumab (FCC) provided synergistic cytotoxicity with effective clearing of minimal residual disease. This phase 2 study determined FCC efficacy and safety in relapsed/refractory CD52+ B-CLL after ⩾ 1 line of treatment. From January 2005 through June 2008, up to 6 courses of oral fludarabine 40 mg/m2 per day, oral cyclophosphamide 250 mg/m2 per day, and subcutaneous alemtuzumab (Mab-Campath) 10 mg(increased to 20 mg after first 10-patient cohort) were administered days 1 to 3 every 28 days. The primary objective was overall response rate (ORR); secondary objectives included response duration, time to disease progression, and safety and tolerability. ORR was 67% in 43 patients; 30% achieved complete response. ORR significantly improved with 1 versus ⩾ 2 prior therapies (P = .018), and without versus with previous monoclonal antibody treatment (P = .003). Median progression-free survival was 24.4 months, not reached in patients achieving complete response. Median overall survival was 33.6 months. Myelosuppression was the most common adverse event, with a low percentage of cytomegalovirus reactivations and manageable infections. However, close vigilance of opportunistic infections is warranted. FCC provides effective immunotherapy in relapsed/refractory CLL, including in patients with poor-risk prognostic factors. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

19. c-Myc modulation & acetylation is a key HDAC inhibitor target in cancer

Author

Ciro Abbondanza, Mariarosaria Conte, Angela Nebbioso, Vincenzo Carafa, Lucia Altucci, Gabriella Lania, Valeria Belsito Petrizzi, Francesco Iovino, Francesco Paolo Tambaro, Hendrik G. Stunnenberg, Concetta Ingenito, Isabella Pallavicini, Rosaria Benedetti, Matthias Nees, Guillermo Garcia-Manero, Joost H.A. Martens, Saverio Minucci, Nebbioso, Angela, Carafa, Vincenzo, Conte, Mariarosaria, Tambaro, Francesco Paolo, Abbondanza, Ciro, Martens, Joost H. A, Nees, Matthia, Benedetti, Rosaria, Pallavicini, Isabella, Minucci, Saverio, Garcia Manero, G, Iovino, Francesco, Lania, Gabriella, Ingenito, Concetta, Belsito Petrizzi, Valeria, Stunnenberg, Hendrik G, and Altucci, Lucia

Subjects
0301 basic medicine, Cancer Research, Sp1 Transcription Factor, Kruppel-Like Transcription Factors, Histone Deacetylase 1, Proto-Oncogene Proteins c-myc, TNF-Related Apoptosis-Inducing Ligand, 03 medical and health sciences, Cell Line, Tumor, Neoplasms, hemic and lymphatic diseases, medicine, Humans, Molecular Biology, Regulation of gene expression, Clinical Trials as Topic, Gene Expression Regulation, Leukemic, business.industry, Myeloid leukemia, Cancer, Acetylation, medicine.disease, c-Myc modulation, 3. Good health, Histone Deacetylase Inhibitors, Leukemia, 030104 developmental biology, Oncology, Apoptosis, Immunology, Cancer cell, Cancer research, Histone deacetylase, business, Ex vivo, Protein Binding, Signal Transduction
Abstract

Histone deacetylase inhibitors (HDACi) are promising anticancer drugs. Although some HDACi have entered the clinic, the mechanism(s) underlying their tumor selectivity are poorly understood. Experimental Design/Results: Using gene expression analysis, we define a core set of 6 genes commonly regulated in acute myeloid leukemia (AML) blasts and cell lines. c-Myc, the most prominently modulated, is preferentially altered in leukemia. Upon HDACi treatment, c-Myc is acetylated at lysine 323 and its expression decreases, leading to TRAIL activation and apoptosis. c-Myc binds to the TRAIL promoter on the proximal GC box through Sp1 or Miz1, impairing TRAIL activation. HDACi exposure triggers TRAIL expression, altering c-Myc-TRAIL binding. These events do not occur in normal cells. Excitingly, this inverse correlation between TRAIL and c-Myc is supported by HDACi treatment ex vivo of AML blasts and primary human breast cancer cells. The predictive value of c-Myc to HDACi responsiveness is confirmed in vivo in AML patients undergoing HDACi-based clinical trials. Purpose: Histone deacetylase inhibitors (HDACi) are promising anticancer drugs. Although some HDACi have entered the clinic, the mechanism(s) underlying their tumor selectivity are poorly understood. Experimental Design and Results: Using gene expression analysis, we define a core set of six genes commonly regulated in acute myeloid leukemia (AML) blasts and cell lines. MYC, the most prominently modulated, is preferentially altered in leukemia. Upon HDACi treatment, c-Myc is acetylated at lysine 323 and its expression decreases, leading to TRAIL activation and apoptosis. c-Myc binds to the TRAIL promoter on the proximal GC box through SP1 or MIZ1, impairing TRAIL activation. HDACi exposure triggers TRAIL expression, altering c-Myc-TRAIL binding. These events do not occur in normal cells. Excitingly, this inverse correlation between TRAIL and c-Myc is supported by HDACi treatment ex vivo of AML blasts and primary human breast cancer cells. The predictive value of c-Myc to HDACi responsiveness is confirmed in vivo in AML patients undergoing HDACi-based clinical trials. Conclusions: Collectively, our findings identify a key role for c-Myc in TRAIL deregulation and as a biomarker of the anticancer action of HDACi in AML. The potential improved patient stratification could pave the way toward personalized therapies.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results